GW Pharma scores another PhIII win for its cannabinoid in rare form of epilepsy

GW Pharma scores another PhIII win for its cannabinoid in rare form of epilepsy

Submitted by admin on May 6, 2019 - 7:35pm
Source: 
Endpoints
News Tags: 
GW Pharma
clinical trials
Epidiolex
cannabindoids
tuberous sclerosis complex
Headline: 
GW Pharma scores another PhIII win for its cannabinoid in rare form of epilepsy
snippet: 

GW Pharmaceuticals can now boast about its fifth straight successful Phase III trial for its cannabinoid drug Epidiolex.

Do Not Allow Advertisers to Use My Personal information